A Decade of Drift

How U.S. Testosterone Regulation Reached a Crossroads

The FDA’s approach to testosterone therapy has undergone one of the most unusual and dramatic evolutions in modern drug regulation.

What began as a cautious, evidence-driven posture in 2014 has, by late 2025, veered into a set of recommendations that experts say stretch far beyond the available science.

To understand why the December 2025 panel meeting set off alarm bells across the medical and regulatory communities, let’s revisit how we got here.

The Era of Caution (2014–2015)

A decade ago, testosterone was already being aggressively marketed as a cure-all for aging: fatigue, weight gain, low libido, depression, “brain fog.” Yet none of those uses were approved by the FDA.

In 2014, after accumulating reports of heart attack, stroke, and death among testosterone users, the agency issued a formal Drug Safety Communication.

The message was direct: TRT was approved only for men with specific medical causes of hypogonadism – not for age-related decline – and the possibility of cardiovascular risk could not be ignored.

In 2015, that caution became policy. FDA required manufacturers to update labels, emphasize the limited indications, and note the possible risk of serious cardiovascular events. The agency also ordered a large clinical trial to directly study long-term safety.

The door to mass-market testosterone use did not shut entirely, but it narrowed.

Blood Pressure Concerns Emerge (2016–2018)

While the public debate fixated on heart attack and stroke, FDA scientists were concerned about something more subtle: blood pressure.

Through premarket studies on new formulations – and later through mandated postmarket studies – the agency found a consistent pattern across delivery methods:

All testosterone products raised blood pressure to a measurable degree

By 2018, FDA required every manufacturer to conduct additional studies, publishing a clear and class-wide relationship between TRT and hypertension.

This new safety signal reinforced the agency’s careful, incremental approach.

The Market Grows Anyway (2019–2022)

Despite FDA warnings, testosterone clinics flourished, fueled by direct-to-consumer advertising and the rise of “Low-T centers” offering broad, symptom-based diagnoses.

Men increasingly obtained testosterone outside of traditional medical care – sometimes through prescribers unfamiliar with endocrine therapy, sometimes through compounding or black-market sources.

Meanwhile, endocrinologists and urologists continued operating under one standard:
Testosterone therapy is appropriate when – and only when – true hypogonadism is diagnosed through clinical symptoms and laboratory confirmation.

But the disconnect between professional guidance and the commercial marketplace was widening.

A Turning Point: The TRAVERSE Trial (2023)

A major shift arrived with the publication of the TRAVERSE trial in 2023. This 5,246-patient randomized controlled study found that, in men with properly diagnosed hypogonadism, testosterone did not increase major cardiovascular events compared to placebo.

It was a meaningful reassurance – but with one critical caveat. TRAVERSE did not evaluate testosterone for age-related low T. The participants were men with medical hypogonadism, not the millions marketed to by “Low-T” clinics.

Still, TRAVERSE supplied the evidence FDA needed to revisit early warnings – just not to rewrite the entire regulatory framework.

A Measured Adjustment (February 2025)

Using TRAVERSE data, FDA took a balanced step. The agency removed the long-standing boxed warning about cardiovascular risk – but simultaneously added a new class-wide warning about increased blood pressure, a safety signal documented through years of ABPM studies.

FDA also kept the “Limitation of Use” stating that testosterone is not approved for age-related declines.

After a decade of debate, the agency had made a cautious, evidence-aligned adjustment.

The December Shift: Science Gives Way to Advocacy (2025)

Then came December 10, 2025. At an FDA-convened expert meeting, panelists recommended a sweeping overhaul that startled many observers.

• • remove longstanding prostate cancer warnings;
  • eliminate the Schedule III controlled-substance classification;
  • broaden TRT indications to nearly all symptomatic men with low testosterone;
  • treat testosterone deficiency as a public health issue requiring routine screening; and
  • align FDA rules with professional society guidelines despite differing scientific thresholds.

For the first time in the history of testosterone regulation, the panel’s recommendations appeared to be driven not by safety data – but by access advocacy and anti-stigma messaging.

Crucially, nothing in TRAVERSE, or in any other clinical trial, supported expanding TRT to men with age-related low testosterone or removing controls designed to prevent misuse and dependency.

A System Under Pressure

The rapid pivot at this meeting mirrors concerns raised in other parts of federal health policy: decisions made without transparent data, established advisory processes, and clear lines between science and political ideology.

The testosterone debate is no longer just about men’s health – it is now a case study in what happens when evidence-based regulation collides with broader policy agendas.

Where Things Stand Now

The FDA has not yet adopted the panel’s recommendations. If implemented, they would mark the most dramatic reduction in oversight of testosterone therapy in U.S. history.

And because testosterone misuse has real-world consequences – including hypertension, infertility, mood instability, dependency, and cardiac events – the stakes are high.

For now, the agency’s ten-year trajectory tells a cautionary story. Science moves slowly, but policy can pivot overnight.

We will continue monitoring developments, evaluating data, and providing analysis as the FDA determines whether to uphold a decade of evidence-based regulation, or follow the December panel down a new and uncertain path.